Who
Timothy Van Hauwermeiren
Director
Company insider
Files Form 4 as: Director, Lexeo Therapeutics; Director, Denali Therapeutics; Director, iTeos Therapeutics; Director, RayzeBio.
In numbers
- Trades disclosed
- 20
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 4
- Companies where not an officer
- 4
- First trade
- 23 Jul 2020
- Last trade
- 25 Jun 2026
- Last filed
- 29 Jun 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 25 Jun 2026filed 29 Jun 2026 | LXEO Lexeo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
| 25 Jun 2026filed 29 Jun 2026 | LXEO Lexeo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
| 3 Jun 2026filed 5 Jun 2026 | DNLI Denali TherapeuticsBiotechnology | SEC FORM 4 Code A | —6,408 at $0.00 | filing |
| 3 Jun 2026filed 5 Jun 2026 | DNLI Denali Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —19,226 at $0.00 | filing |
| 3 Jun 2026filed 5 Jun 2026 | DNLI Denali Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —19,226 at $0.00 | filing |
| 3 Jun 2026filed 5 Jun 2026 | DNLI Denali TherapeuticsBiotechnology | SEC FORM 4 Code A | —6,408 at $0.00 | filing |
| 4 Nov 2025filed 6 Nov 2025 | DNLI Denali Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —31,897 at $0.00 | filing |
| 4 Nov 2025filed 6 Nov 2025 | DNLI Denali TherapeuticsBiotechnology | SEC FORM 4 Code A | —10,632 at $0.00 | filing |
| 26 Jun 2025filed 30 Jun 2025 | LXEO Lexeo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,916 at $0.00 | filing |
| 13 May 2025filed 14 May 2025 | iTeos Therapeuticsoption or derivative | SEC FORM 4 Code M | —22,346 at $0.00 | filing |
| 13 May 2025filed 14 May 2025 | iTeos Therapeutics | SEC FORM 4 Code M | $96K22,346 at $4.30 | filing |
| 5 Jul 2024filed 8 Jul 2024 | LXEO Lexeo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —36,000 at $0.00 | filing |
| 11 Jun 2024filed 13 Jun 2024 | iTeos Therapeuticsoption or derivative | SEC FORM 4 Code A | —24,200 at $0.00 | filing |
| 26 Feb 2024filed 27 Feb 2024 | RayzeBiooption or derivative | SEC FORM 4 Code D | —48,628 | filing |
| 1 Nov 2023filed 1 Nov 2023 | RayzeBiooption or derivative | SEC FORM 4 Code A | —48,628 at $0.00 | filing |
| 13 Jun 2023filed 15 Jun 2023 | iTeos Therapeuticsoption or derivative | SEC FORM 4 Code A | —22,383 at $0.00 | filing |
| 9 Jun 2022filed 10 Jun 2022 | iTeos Therapeuticsoption or derivative | SEC FORM 4 Code A | —17,538 at $0.00 | filing |
| 17 Jun 2021filed 21 Jun 2021 | iTeos Therapeuticsoption or derivative | SEC FORM 4 Code A | —16,608 at $0.00 | filing |
| 23 Jul 2020filed 21 Oct 2020 | iTeos Therapeuticsoption or derivative | SEC FORM 4 Code A | —16,608 at $0.00 | filing |
| 23 Jul 2020filed 24 Jul 2020 | iTeos Therapeuticsoption or derivative | SEC FORM 4 Code A | —16,608 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.